Orphanet: Glycogen storage disease due to muscle glycogen phosphorylase deficiency

(*) Required fields.

You are (*)

If you have selected the “Other” category, please specify which type of user you are: *

Email address: *

Topic of your comment *

Epidemiology data

Clinical signs

Nomenclature and/or coding

Your message *

(3000 characters remaining)

Attention

Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Check this box if you wish to receive a copy of your message

Please reproduce the text below: *

Glycogen storage disease due to muscle glycogen phosphorylase deficiency

ORPHA:368

Classification level: Disorder

Synonym(s):
- GSD due to muscle glycogen phosphorylase deficiency
- GSD type 5
- GSD type V
- Glycogen storage disease type 5
- Glycogen storage disease type V
- Glycogenosis due to muscle glycogen phosphorylase deficiency
- Glycogenosis type 5
- Glycogenosis type V
- McArdle disease
- Myophosphorylase deficiency
Prevalence: Unknown
Inheritance: Autosomal recessive
Age of onset: Infancy, Childhood
ICD-10: E74.0
OMIM: 232600
UMLS: C0017924 C2936916
MeSH: C537276 D006012
GARD: 6528
MedDRA: 10018462

Summary

Epidemiology

Prevalence is unknown.

Clinical description

Onset occurs in childhood. Patients present with a syndrome of muscular exercise intolerance with myalgia, cramps, fatigue, and muscle weakness. Massive elevation of creatine-kinase and rhabdomyolysis with myoglobinuria (dark urine) after exercise is noted in around 50% of patients, potentially leading to acute kidney failure. A 'second wind' phenomenon with relief of myalgia and fatigue after a few minutes of rest is observed in many patients. The clinical presentation is usually very classical, but some patients may have very moderate forms. In a few cases, onset very early in life with hypotonia, generalized muscle weakness and progressive respiratory failure has been described.

Etiology

The condition is caused by mutations in the PYGM gene (11q13), leading to muscle phosphorylase deficiency. Mutation p.R50X may account for 40% to 50% of the alleles in Caucasian populations.

Diagnostic methods

The diagnosis is based on biological findings revealing a lack of lactate elevation in blood during ischemic forearm test, excess glycogen, and deficient phosphorylase activity in the muscle biopsy.

Differential diagnosis

The differential diagnosis should include GSD type 7 (see this term).

Genetic counseling

The condition is autosomal recessive.

Management and treatment

Treatment is based on controlled physical training in order to develop mitochondrial oxidation capacities in muscles, and programmed glucose intake according to exercising periods. Diets with high protein intake have yielded variable results.

Prognosis

Prognosis is favorable when severe rhabdomyolysis is avoided. However, myoglobinuria may lead to potentially life-threatening renal failure.

Expert reviewer(s): Dr Roseline FROISSART - Last update: September 2009

The portal for rare diseases and orphan drugs

Search for a rare disease

Other search option(s)